Rapport Therapeutics, Common Stock Today
| RAPP Stock | 22.84 0.45 2.01% |
Performance4 of 100
| Odds Of DistressLess than 49
|
Rapport Therapeutics, is selling at 22.84 as of the 1st of December 2024; that is 2.01 percent up since the beginning of the trading day. The stock's last reported lowest price was 21.9. Rapport Therapeutics, has 49 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Rapport Therapeutics, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of June 2024 | Category Healthcare | Classification Health Care |
Rapport Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 36.58 M outstanding shares of which 1.74 M shares are at this time shorted by private and institutional investors with about 11.75 trading days to cover. More on Rapport Therapeutics, Common
Moving against Rapport Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rapport Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Abraham MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
| Rapport Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rapport Therapeutics,'s financial leverage. It provides some insight into what part of Rapport Therapeutics,'s total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||||||||||||
Rapport Therapeutics, Common (RAPP) is traded on NASDAQ Exchange in USA. It is located in 1325 Boylston Street, Boston, MA, United States, 02215 and employs 10 people. Rapport Therapeutics, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 762.25 M. Rapport Therapeutics, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 36.58 M outstanding shares of which 1.74 M shares are at this time shorted by private and institutional investors with about 11.75 trading days to cover.
Rapport Therapeutics, generates negative cash flow from operations
Check Rapport Therapeutics, Probability Of Bankruptcy
Ownership AllocationThe majority of Rapport Therapeutics, Common outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rapport Therapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rapport Therapeutics,. Please pay attention to any change in the institutional holdings of Rapport Therapeutics, as this could imply that something significant has changed or is about to change at the company.
Check Rapport Ownership Details
Rapport Therapeutics, Historical Income Statement
Rapport Stock Against Markets
Rapport Therapeutics, Corporate Management
| Troy Ignelzi | Chief Officer | Profile | |
| Bradley MD | Chief Officer | Profile | |
| Cheryl Gault | Chief Officer | Profile | |
| Swamy Yeleswaram | Chief Officer | Profile | |
| Kathleen Wilkinson | Chief Officer | Profile |
Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.